Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2FY27 revenue grew 52% y-y to INR4,314 million; H1 revenue up 52% y-y to INR8,241 million - EBITDA rose 50% y-y to INR1,020 million; margin improved to 23.6%, adjusted margin 28% - Group PAT INR485 million in Q2, up 17% y-y; cash profit up 36% y-y - ARPOB increased 11% y-y to INR36,000; occupancy at 72% - Strategic partnership with Advent International for INR3,150 Cr to add 2,000 beds over 3-5 years - New hospitals ramping up; Model Town Delhi expected to break even in H2FY27 - Oncology drug price capping impact minimal (0.3% EBITDA reduction), margin guidance unchanged - Gurugram hospital expected to break even in 15 months with premium ARPOB - International business grew 35% H2FY26 to H1FY27; targeting CIS, Africa; still single-digit revenue share - Debt peaked due to Gurugram capex and equipment; expected to decline going forward - Expansion focus on multi-specialty, EBITDA-positive hospitals, mostly equity-owned - Government business share reducing in new hospitals to ~15-20% - Management confident of maintaining 24%+ EBITDA margin despite regulatory changes - Multiple analyst queries on Advent deal tranches, expansion plans, oncology segment, and payer mix